candesartan hidroclorotiazida aurobindo 32 mg/25 mg
apl swift services (malta) limited - malta - combinatii (candesartanum cilexetil+hct) - compr. - 32mg/25mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic
candesartan hidroclorotiazida aurobindo 8 mg/12,5 mg
apl swift services (malta) limited - malta - combinatii (candesartanum cilexetil+hct) - compr. - 8mg/12,5mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - fibroză chistică - alte produse ale sistemului respirator - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 și 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 și 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
rofloxan 2 mg/ml soluţie perfuzabilă
rotapharm ilaclari limited sirketi - metoclopramidum - soluţie perfuzabilă - 2 mg/ml
levox-500 500 mg comprimate filmate
tulip lab private limited - levofloxacinum - comprimate filmate - 500 mg
levox-750 750 mg comprimate filmate
tulip lab private limited - levofloxacinum - comprimate filmate - 750 mg
moxicum 400 mg comprimate filmate
dr. sertus ilac sanayi ve ticaret limited sirketi - moxifloxacinum - comprimate filmate - 400 mg
levofloxacina aurobindo 5 mg/ml
apl swift services (malta) limited - malta - levofloxacinum - sol. perf. - 5mg/ml - chinolone antibacteriene fluorochinolone
moxifloxacina aurobindo 400 mg
apl swift services (malta) limited - malta - moxifloxacinum - compr. film. - 400mg - chinolone antibacteriene fluorochinolone
flaprox 500 mg comprimate filmate
rotapharm ilaclari limited sirketi - ciprofloxacinum - comprimate filmate - 500 mg